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Germany.Mono-glucosylation of (H/K/N)Ras by Clostridium sordellii lethal toxin (TcsL) blocks critical survival
signaling pathways, resulting in apoptosis. In this study, TcsL and K-Ras knock-down by siRNA are
presented to result in expression of the cell death-regulating small GTPase RhoB. TcsL-induced RhoB
expression is based on transcriptional activation involving p38alpha MAP kinase. Newly synthesized
RhoB protein is rapidly degraded in a proteasome- and a caspase-dependent manner, providing ﬁrst
evidence for caspase-dependent degradation of a Rho family protein. Although often characterised
as a pro-apoptotic protein, RhoB suppresses caspase-3 activation in TcsL-treated ﬁbroblasts. The
ﬁnding on the cytoprotective activity of RhoB in TcsL-treated cells re-enforces the concept that RhoB
exhibits cytoprotective rather than pro-apoptotic activity in a cellular background of inactive Ras.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The low molecular mass GTP binding proteins RhoA, RhoB and
RhoC act as molecular switches, as they cycle between an active
GTP-bound conformation and an inactive GDP-bound conforma-
tion. Rho-GTPases regulate the actin dynamics, cell adhesion, cell
cycle progression, gene transcription, intracellular membrane traf-
ﬁcking, and cell survival [1]. These functions are important in
tumorigenesis and tumor progression [2]. RhoA and RhoC are
over-expressed in various types of tumors, and over-expression
of RhoC protein has been shown to correlate with tumor metastasis
[3,2]. The role of RhoB in human cancer development is controver-
sial. RhoB has been found to be down-regulated in head and neck
carcinoma and gastric and lung cancer but overexpressed in breast
cancer [4,2]. Due to its pro-apoptotic activity RhoB is generally re-chemical Societies. Published by E
EF, mouse embryonic ﬁbro-
erotype F strain 1470; TcsL,
rsodesoxycholic acid
. Genth).
sität Mainz, D-55131 Mainz,garded as a tumor suppressor [5]. RhoB expression signiﬁcantly
inhibits proliferation, migration and invasion of cancer cells and
also enhances chemosensitivity of malignant cells to anticancer
drugs [6–9].
RhoB is an immediate-early gene product with a short half life
period. RhoB expression has been reported in response to extracel-
lular stimuli such as growth factors, cytotoxic and genotoxic agents
[10–12]. The low intracellular level of RhoB is maintained by
repression of rhoB promoter activity by oncogenes, including the
epidermal growth factor receptor (EGFR), ErbB2, and Ras [8,9].
Farnesyltransferase inhibitors (FTIs) inhibits Ras through preven-
tion of posttranslational farnesylation. FTI-induced Ras inhibition
results in RhoB expression [13]. RhoB has been identiﬁed as a tar-
get in cancer therapy, based on the concept that RhoB expression is
required for apoptosis of transformed cells [5,14].
Lethal Toxin from Clostridium sordellii (TcsL) is the major
virulence factor of C. sordellii-associated disease in animals and
humans, which includes myonecrosis, sepsis and shock [15,16].
TcsL enters target cells by receptor-mediated endocytosis and efﬁ-
caciously mono-glucosylates (and thereby inactivates) the Ras sub-
type proteins (H/K/N)Ras and Rap(1/2). TcsL less efﬁcaciously
glucosylates Rac1 and Cdc42, while Rho(A/B/C) are not glucosylated
[17–19]. Treatment of cells with TcsL results in inhibition of PI3K/lsevier B.V. All rights reserved.
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with both effects contributing to the initiation of apoptosis of cul-
tured myeloid and epithelial cells [20–23].
In this study, TcsL-induced RhoB expression is characterised in
detail. TcsL treatment is presented to result in pronounced RhoB
expression based on transcriptional activation involving p38alpha
MAP kinase. RhoB, that is not glucosylated by TcsL, becomes acti-
vated in TcsL-treated cells and protects cells from TcsL-induced
apoptosis. RhoB is caspase-dependently degraded, which is inter-
preted in terms of an ampliﬁcation of pro-apoptotic signaling pro-
cess initiated by the toxin. This is the ﬁrst report showing that a
Rho subtype protein is degraded in a caspase-dependent manner.
2. Materials and methods
2.1. Materials
Toxin B (TcdBF) and TcsL were puriﬁed from the Clostridium dif-
ﬁcile serotype F strain 1470 and the Clostridium sordellii strain
6018, respectively [24]. The GST-C21 vector construct was a kind
gift of Dr. John Collard (Amsterdam). Commercially obtained re-
agents: Actinomycin D (Calbiochem), cycloheximide (Calbiochem),
caspase inhibitor I. (Z-VAD(OMe)-fmk) (Calbiochem), LY294002
(Calbiochem), MG132 (Calbiochem), SB203580 (Calbiochem),
Tauroursodeoxycholic acid (Sigma); antibodies: K-Ras(Mab F234,
SantaCruz); Ras(Mab27H5, Cell Signaling); Rac1(Mab 102; Trans-
duction Lab); Rac1(Mab 23A8, Upstate); RhoA(Mab 26C4, Santa-
Cruz); RhoB (Mab C-5, SantaCruz); beta-actin(Mab AC-40, Sigma),
and horseradish peroxidase conjugated secondary antibodies rab-
bit/mouse (Rockland).
2.2. Methods
2.2.1. Cell culture
NIH3T3 ﬁbroblasts, E1A/Ras-transformed RhoB +/ and RhoB
/ mouse embryonic ﬁbroblasts (MEFs) (kindly provided by Dr.
George Prendergast, Lankenau Institute for Medical Research,
Wynnewood, Pennsylvania) [7,25], and p38alpha/ and the corre-
sponding p38alpha wt MEFs (kindly provided by Dr. Angel Nebreda,
Institute for Research in Biomedicine, Barcelona, Spain) [26] were
cultivated in Dulbecco’s modiﬁed essential medium (Bio-
chrom + 10% FCS, 100 lg/ml penicillin, 100 U/ml streptomycin
and 1 mM sodium pyruvate) at 37 C and 5% CO2 according to
standard protocols. For all experiments, cells were seeded sub-
conﬂuently into 3.5 cm-diameter dishes. Cells were washed once
with phosphate buffered saline. They were then scraped into
Laemmli sample buffer (200 ll). The obtained suspension was
incubated for 10 min at 37 C and 1400 rpm in a thermo shaker
and subsequently soniﬁed on ice. The lysate was then incubated
for 10 min at 95 C and submitted to Western blot analysis.
2.2.2. RhoB activity assay
The Rho-binding domain of Rhotekin, C21, was expressed as
GST-fusion protein in Escherichia coli. After their lysis using French
Press, the soluble fraction was obtained by centrifugation
(20.000 rpm, 200). It was incubated with glutathione–Sepharose
for 300 at 4 C and subsequently washed. 3T3 ﬁbroblasts treated
with either TcdBF or TcsL as indicated were lysed in lysis buffer
(50 mM Tris pH 7.2, 150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM
PMSF, 5 mM DTT, Complete –EDTA). The soluble fraction was ob-
tained by centrifugation (10000g, 50). It was then added to the
glutathione-bound GST-C21 for 1 h (4 C). After washing of the
beads, RhoB was eluted by incubation with Laemmli sample buffer
at 95 C (100). Samples were submitted to SDS–PAGE and Western
blotting.2.2.3. Knockdown of gene expression using siRNAs
The following Ras-speciﬁc siRNAs were used in this study: siR-
NA to H-Ras, GAGUGGAGGAUGCCUUCUA; siRNA to K-Ras, GCUC
AGGACUUAGCAAGAA; and siRNA to N-Ras, AAAGCGCACUGA
CAAUCCA. These siRNAs (20 nM) were transfected into Hela cells
(n = 50,000) by using JetPRIME transfection reagent (PeqLab, Erlan-
gen, Germany) according to the manufacturer’s protocol. After
48 h, the effects of knockdown on RhoB expression were assessed.
The level of protein knockdown by siRNA was determined by Wes-
tern-blot analysis.
2.2.4. RNA puriﬁcation and RT-reaction
Total RNA was puriﬁed from ﬁbroblasts using the RNeasy Mini
Kit (Qiagen) according to the manufacturer’s instructions. Shortly,
cells were lysed in lysis buffer. The RNA was extracted and bound
to silica membranes after addition of ethanol. Contaminating DNA
was cleaved by DNase I digestion and bound RNA washed with the
supplied buffer. Total cellular RNA was then eluted with RNase free
water. 2 lg of RNA were then used as template in the RT-reaction,
which was performed with the Omniscript RT-Kit (Qiagen) accord-
ing to the manufacturer’s instructions.
2.2.5. Semi-quantitative real-time PCR
The real-time PCR was conducted using the QuantiTect SYBR
Green PCR Kit (Qiagen) and a LightCycler (Roche). The cDNA ob-
tained from the RT-reaction was diluted (1:1000) to avoid over-
loading. Primers (3 lM) used were: b-actin: 50-CCT GCT TGC TGA
TCC ACA TC-30 and 50-GCA TTG CTG ACA GGA TGC AG-30, RhoB:
50-CCG AGG TAA AGC ACT TCT GC-30 and 50-CCG AGC ACT CGA
GGT AGT CA-30. After every run, a melting curve was recorded to
ensure the speciﬁcity of the reaction.
2.2.6. Analysis of rhoB promoter activity
Subconﬂuent NIH3T3 ﬁbroblasts were transiently transfected
with 2 lg of the 3.5 kb rhoB promoter CAT construct [10] for
14 h, applying FuGENE 6 Transfection Reagent (Roche). Cells were
then treated as indicated and harvested. The protein concentration
of the lysates was normalized using Bradford test. The level of CAT
expression was analyzed using an enzyme-linked immunosorbent
assay (CAT-Elisa kit, Roche) according to the manufacturer’s
instructions.
2.2.7. Caspase-3 colorimetric assay
Caspase-3 activity was analyzed using the Caspase-3 colorimet-
ric assay (R&D Systems), according to the manufacturer’s instruc-
tions. Cells were exposed to the toxins and drugs as indicated.
Cells were lysed and subsequently incubated with the colorimetric
substrate DEVD-pNA at 37 C for 3 h. The caspase-3-dependent re-
lease of the reporter molecule pNA was quantiﬁed by photometry
using a scanning multi-well spectrophotometer at 405 nm.
3. Results
3.1. TcsL-induced expression and activation of RhoB
Pronounced RhoB expression was observed upon treatment of
NIH3T3 ﬁbroblasts with increasing concentrations of TcsL
(Fig. 1A). TcsL-catalysed glucosylation of (H/K/N)Ras and Rac1
was evidenced using the glucosylation-sensitive Ras(27H5) and
Rac1(102) antibodies, respectively [27,17]. Either antibody recog-
nizes glucosylation in terms of apparently decreasing levels of
either (H/K/N)Ras or Rac1 protein (Fig. 1A). (H/K/N)Ras was more
efﬁcaciously glucosylated than Rac1 (Fig. 1A), consistent with
former observations [17]. The levels of K-Ras or Rac1 were not
changed upon TcsL treatment, as analyzed using alternative
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Fig. 1. RhoB expression and activation in TcsL-treated cells. (A) Correlation of Ras glucosylation and RhoB expression. NIH3T3 ﬁbroblasts were exposed to the indicated
concentrations of TcsL for 4 h. Cells were lysed and submitted to immuno-blot analysis using the indicated antibodies. Immuno-blots from representative experiments are
presented (n = 3). Signal intensities obtained from immuno-blots applying the glucosylation-sensitive Ras(27H5) antibody (ﬁlled squares), the glucosylation-sensitive
Rac1(102) antibody (open squares), and the RhoB antibody (ﬁlled triangles) from TcsL-treated cells were quantiﬁed and normalized to beta-actin. The concentration of either
(H/K/N)Ras, Rac1, or RhoB from non-treated cells was set 1.0. Results displayed are the mean of three independent experiments. (B) Difference in RhoB expression between
TcsL and TcdBF. Fibroblasts were exposed to TcsL (3 lg/ml) or TcdBF (30 ng/ml) for the indicated times. Cells were then lysed and analysed for the cellular level of RhoB-GTP
using GST-rhotekin-C21 pulldown assay. GST alone served as a negative control. Total and precipitated RhoB was detected by immuno-blot analysis. A sample treated with
TcsL for 7 h subjected to nucleotide exchange with the non-hydrolysable GTPcS indicated the level of maximal level of active RhoB-GTPcS, which was set 1.0. Signal
intensities of RhoB activation induced by either TcsL (ﬁlled squares) or TcdBF (ﬁlled triangles) were quantiﬁed, normalized, and were given relative to the maximal level of
RhoB-GTP[S].
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sion was also characterized in a time-dependent experiment
(Fig. 1B, S1). After about 7 h of TcsL treatment, the RhoB level
was elevated by about 10-fold (compared to the RhoB level in
non-treated cells) and reached a steady state level (Fig. S1). Ele-
vated RhoB level persisted for at least 17 h (Fig. S1). TcsL-induced
RhoB expression was accompanied by a higher level of RhoB-GTP
(Fig. 1B), as analysed by Rhotekin pull-down assay. RhoB, that is
not glucosylated by TcsL, was thus activated in TcsL-treated cells.
Taken together, TcsL induced RhoB expression and RhoB activation.
3.2. Critical role of (H/K/N)Ras inhibition in TcsL-induced RhoB
expression
To provide evidence that (H/K/N)Ras glucosylation was essen-
tial for TcsL-induced RhoB expression, we exploited the related
Rac-glucosylating variant toxin B from the C. difﬁcile serotype F
strain 1470 (TcdBF). TcdBF glucosylates speciﬁcally Rac1 but not
(H/K/N)Ras [17,28]. TcsL and TcdBF were applied in equipotent
concentrations with respect to Rac1 glucosylation (Fig. S2). TcsL,
but not TcdBF, glucosylated (H/K/N)Ras and caused a decrease of
the level of the phosphorylated form of the Ras downstream target
p44/42 MAP kinase (ERK) (Fig. S2). TcsL (but not TcdBF) stimulated
RhoB expression (Fig. 1B). This observation strongly suggested that
(H/K/N)Ras glucosylation (rather than Rac1 glucosylation) is re-
quired for RhoB expression.
TcdBF treatment resulted in RhoB activation, although it did not
induce RhoB protein expression (Fig. 1B). To further show that
RhoB expression was based on Ras inhibition, RhoB expressionwas analysed in HeLa cells with (H/K/N)Ras knocked-down by
a siRNA based method (Fig. 2A). Efﬁcient knock-down of
(H/K/N)Ras was conﬁrmed using the (H/K/N)Ras-speciﬁc antibody
Ras(mAb27H5) (Fig. 2A) [17]. (H/K/N)Ras knock-down induced
RhoB expression (Fig. 2A), showing that (H/K/N)Ras inhibition is
sufﬁcient to stimulate RhoB expression. (H/K/N)Ras knock-
down-induced RhoB expression was less efﬁcaciously compared
to RhoB expression stimulated by (H/K/N)Ras glucosylation. This
difference correlated with the observation that TcsL completely
inhibited (H/K/N)Ras, while traces of (H/K/N)Ras were still detect-
able upon (H/K/N)Ras knock-down (Fig. 2A). The low amount of
residual (H/K/N)Ras were in fact responsible for reduced RhoB
expression in cells with (H/K/N)Ras knocked-down, as TcsL treat-
ment of these cells resulted in an increase in RhoB expression to
an extent comparable to that observed in TcsL-treated cells
(Fig. 2A). These observations showed that inhibition of Ras by
either depletion or glucosylation resulted in RhoB expression.
The observation that TcsL induced RhoB expression to comparable
extent in cells with and without (H/K/N)Ras knocked-down further
showed that glucosylation of Ras resulted in mere Ras inhibition
but not in a gain of dominant-negative function of Ras. TcdBF
treatment of cells with (H/K/N)Ras knocked down resulted in par-
tial Rac1 glucosylation but did neither reduced the level of active
Ras nor augmented RhoB expression (Fig. 2A). These observations
excluded that Rac1 glucosylation triggered RhoB expression.
Next, the Ras isoform involved in RhoB expression was identi-
ﬁed by knock-down of individual Ras isoforms in Hela cells. RhoB
expression was speciﬁcally observed upon knock-down of K-Ras
(neither of H-Ras nor N-Ras) (Fig. 2B). K-Ras knock-down was
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Fig. 2. RhoB expression upon Ras knock-down. (A) HeLa cells were transfected with
siRNAs targeting H-Ras, K-Ras and N-Ras or with scrambled control siRNA (scr) as
indicated for 48 h. Cells were subsequently treated with TcsL (5 lg/ml) or buffer for
4 h. The cellular levels of Ras and RhoB were analyzed by immuno-blot analysis.
Signal intensities obtained from RhoB immuno-blots were quantiﬁed and normal-
ized to beta-actin. Results displayed are the mean ± S.D. of three independent
experiments. A P-value < 0.05 (⁄) was considered as statistically signiﬁcant. (B) Ras
depletion-induced RhoB expression. HeLa cells exposed to H-Ras-, K-Ras, or N-Ras-
speciﬁc siRNA or scrambled (scr) siRNA as indicated for 48 h. Cells were lysed and
submitted to immuno-blot analysis using the indicated antibodies. Immuno-blots
from representative experiments are presented. Signal intensities obtained from
immuno-blots applying the RhoB antibody were quantiﬁed and normalized to beta-
actin. The RhoB level from non-treated cells was set 1.0. Results displayed are the
mean ± S.D. of three independent experiments. A P-value < 0.05 (⁄) was considered
as statistically signiﬁcant as compared with non-treated cells.
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Fig. 3. Critical role of PI3K in TcsL-induced RhoB expression. NIH3T3 ﬁbroblasts
were treated with TUDCA (300 lM), Ly294002 (20 lM), and TcsL (3 lg/ml) as
indicated for 4 h. Signal intensities were densitometrically quantiﬁed and normal-
ized to the b-actin signal. The RhoB level from non-treated cells was set to 1.0. Data
shown represent the mean of three independent experiments. P-values < 0.05 (⁄)
and < 0.01 (⁄⁄) were considered as statistically signiﬁcant.
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the use of the K-Ras-speciﬁc antibody K-Ras(mAbF234) (Fig. 2B).
Knock-down of either H-Ras and N-Ras was shown by reduced
Ras proteins levels detection using (H/K/N)Ras-speciﬁc antibody
Ras(mAb27H5) (Fig. 2B) [17]. K-Ras depletion was thus sufﬁcient
for RhoB expression. Apparently, speciﬁcally K-Ras (not H-Ras or
N-Ras) repressed RhoB expression in Hela cells.
3.3. Involvement of PI3K in Ras-dependent RhoB repression
Ras-dependent repression of RhoB has been suggested to in-
volve the Ras downstream effector PI3K [8,9]. Consistent with this
proposal, treatment of ﬁbroblasts with LY294002, an inhibitor of
PI3K, resulted in a moderate RhoB expression (Fig. 3). The hydro-
philic bile acid tauroursodesoxycholic acid (TUDCA), an activator
of PI3K, has recently been reported to preserve PI3K activity down-stream of glucosylated Ras [20,21,29]. Therefore, we hypothesized
that TUDCA-induced activation of PI3K maintains RhoB repression
in TcsL- or LY294002-treated cells. TcsL-induced and LY294002-in-
duced RhoB expression was signiﬁcantly reduced, if ﬁbroblasts
were additionally treated with TUDCA (Fig. 3). This observation
suggested that the maintenance of PI3K activity downstream of
glucosylated Ras preserved RhoB repression and prevented its
expression in TcsL- or LY294002-treated cells. TUDCA treatment
did not prevent TcsL-induced p44/42 MAPK dephosphorylation
(Fig. 3), excluding that TUDCA interfered with TcsL-induced Ras
inactivation and that TUDCA non-speciﬁcally activated Ras down-
stream kinases. TUDCA-mediated PI3K activation (downstream of
glucosylated Ras) thus preserved RhoB repression in TcsL-treated
cells.
3.4. Critical role of transcriptional activation in TcsL-induced RhoB
expression
TcsL-induced RhoB expression was accompanied by a concen-
tration-dependent expression of rhoB-mRNA, as analysed using
real-time RT-PCR (Fig. 4A). TcsL-induced expression of either
rhoB-mRNA (Fig. 4A) or RhoB protein (Fig. 4B) was prevented upon
pre-treatment of cells with actinomycin D. Expression of RhoB pro-
teins was also blocked upon pre-treatment of cells with cyclohex-
imide (Fig. 4B). These ﬁndings strongly suggested that increased
TcsL-induced RhoB expression rests on transcriptional activation.
In fact, TcsL activated the rhoB promoter in a concentration depen-
dent manner, as analysed using a 3.5 kb fragment of the rhoB pro-
moter cloned into pCAT basic as a reporter construct [10] in
NIH3T3 ﬁbroblasts (Fig. 4C).
3.5. Involvement of p38alpha MAP kinase in TcsL-induced RhoB
expression
Several reports suggested a role of p38 MAP kinase in the regu-
lation of RhoB expression [30,31]. TcsL time-dependently activated
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Fig. 4. Critical role of transcriptional activation in TcsL-induced RhoB expression.
(A) TcsL-induced rhoB-mRNA expression. Fibroblasts were treated with the
indicated concentrations of TcsL and actinomycin D (5 lM) as indicated for 4 h.
Subsequently, total mRNA was prepared from treated cells and submitted to real-
time RT-PCR. rhoB signals were normalized to beta-actin signals. The level of rhoB-
mRNA in non-treated cells was set 1.0. Results displayed are the mean ± S.D. of
three independent experiments. (B) Fibroblasts were treated with TcsL (3 lg/ml) or
actinomycin D (Act D, 5 lM) or cyloheximide (CHX, 100 lM) as indicated for 4 h.
Cellular RhoB levels were analysed by immuno-blot analysis. (C) TcsL-induced
activation of the rhoB promoter. NIH3T3 ﬁbroblasts were transfected with the
3.5 kb rhoB promoter CAT-construct followed by treatment of the cells with the
indicated concentrations of TcsL for 7 h. Cells were harvested for analysis of CAT
protein levels using ELISA. Data shown represent the mean (± S.D.) of three
independent experiments.
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levels of pT180/pY182-p38 MAP kinase (Fig. S3). TcsL-induced
Rac1 glucosylation correlated with p38 activation (Fig. S3). Murine
ﬁbroblasts speciﬁcally express p38alpha [32,26], for which reason
the activities of the p38beta/gamma/delta do not have to be considered.
To show that p38alpha is involved in TcsL-induced RhoB expression,
RhoB expression was differentially analysed in SV40-immortalized
p38alpha/ and the corresponding p38alphawildtype MEFs [32,26].
The expression of RhoB protein was reduced in TcsL-treated
p38alpha/MEFs compared to the corresponding p38alphawildtype
MEFs (Fig. 5A), suggesting a role of p38 in the regulation of RhoB
expression. TcsL glucosylated (H/K/N)Ras in both cell lines withcomparable kinetics (Fig. 5A), excluding that reduced RhoB expres-
sion in p38alpha/MEFs was due to attenuated Ras glucosylation.
The activation of the rhoB promoter was more pronounced in
p38alphawildtype MEFs than in p38alpha/MEFs (Fig. 5B). Further-
more, TcsL induced expression of rhoB-mRNA in p38alphawildtype
more efﬁcaciously than in p38alpha/MEFs (Fig. S4). Upon inhibi-
tion of transcription by actionomycin D, cellular rhoB-mRNA levels
decayed with ﬁrst order kinetics in either cell line (Fig. S4). The
half-life of rhoB-mRNA was estimated to 35 ± 4 min in p38alpha-
wildtype and to 38 ± 8 min in p38alpha/ MEFs (Fig. S4). These
observations most likely indicated that p38alpha-mediated stabili-
sation of rhoB-mRNA does not contribute to TcsL-induced
RhoB expression. SB203580 is a pyridinylimidazole inhibitor of
the p38alpha/beta [33]. Pre-treatment of p38alphawildtype MEFs
with SB203580 also resulted in reduced RhoB expression upon
TcsL treatment (Fig. S5), consistent with the ﬁndings obtained
above from p38alpha/ and p38alphawildtype MEFs (Fig. 5A). In
p38alpha/MEFs, the kinetics of TcsL-stimulated RhoB expression
were comparable upon SB203580 treatment, arguing against
an off-target effect of SB203580 (Fig. S5). The glucosylation of
(H/K/N)Ras appeared to be moderately reduced in p38alpha/
ME ﬁbroblasts (Fig. S5), suggesting that SB203580 weakly
interfered with TcsL-catalysed Ras glucosylation. Upon genetic
deletion of p38alpha and pharmacological inhibition of p38alpha by
SB203580, TcsL-induced activation of the rhoB promoter and RhoB
expression was reduced, pointing to a role of p38alpha in regulating
RhoB expression. The inﬂuence of p38alpha in RhoB expression
appeared to be independent of stabilizing rhoB-mRNA.
3.6. Proteasome- and caspase-dependent degradation of RhoB
To check if increased stability of RhoB protein contributed to
TcsL-induced RhoB expression, the half live of RhoB was analysed
in ﬁbroblasts upon TcsL treatment for 4 h. RhoB de novo synthesis
was blockedby cycloheximide and theRhoB level rapidly decreased,
with a half-life of about 50 min (Fig. 6). Rho proteins are well estab-
lished to be subject of proteasome-dependent degradation [34,27].
Interestingly, RhoB degradation was only reduced (not fully pre-
vented), when proteasomal degradation was blocked using the pro-
teasome inhibitorMG132 (Fig. 6). In thepresenceofMG132, half-life
of RhoB increased to about 3 h (Fig. 6). TcsL is well established to in-
duce apoptotic cell death of cultured cells [20,35], leading to the
hypothesis that caspase-dependent degradation of RhoB might
inﬂuence the short RhoB half-life in TcsL-treated cells. In fact, RhoB
degradation was slowed down, when ﬁbroblasts were pre-treated
with Z-VAD-fmk, a broad-spectrum inhibitor of caspases (Fig. 6).
Combined pre-treatment of ﬁbroblasts with MG132 and Z-VAD-
fmk completely blocked RhoB degradation (Fig. 6). These ﬁndings
showthat in TcsL-treatedﬁbroblasts RhoBwasdegraded in aprotea-
some- as well as caspase-dependent manner. The half-life of RhoB
from TcsL-treated ﬁbroblasts of <1 h is clearly below the reported
half-live of RhoB of about 2 h [36],excluding that increased half-live
of RhoB protein contributed to TcsL-induced RhoB expression.
3.7. Cytoprotective effect of RhoB
RhoB is regarded as a sensor of cell damage and and a key reg-
ulator of either cytoprotective responses [37,38] or of apoptotic
cell death [39,7,6]. The role of RhoB in TcsL-induced apoptosis
was comparatively analysed in E1A/Ras(ER)-transformed RhoB+/
and RhoB/ MEFs [25,7]. TcsL-induced RhoB expression was
speciﬁcally observed in RhoB+/ MEFs (Fig. S7). TcsL concentra-
tion-dependently glucosylated (H/K/N)Ras in ER-transformed
RhoB+/ and RhoB/ MEFs (Fig. S6). TcsL-induced activation of
the effector caspase-3 was analyzed in terms of the cleavage of
its colorimetric substrate DEVD-pNA. TcsL induced pronounced
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cient MEFs only moderate caspase-3 activation was observed
(Fig. 7). This ﬁnding suggested that RhoB exhibits a cytoprotective
rather than a pro-apoptotic effect in TcsL-induced apoptosis. Both
Z-VAD-fmk and SB203580 have been described as efﬁcient inhibi-
tors of TcsL-induced apoptosis in several cell culture models
[20,21,35]. In both RhoB+/ and RhoB/MEFs, TcsL-induced cas-
pase-3 activation was completely inhibited by either SB203580 or
Z-VAD-fmk (Fig. 7), suggesting that the cytoprotective effect of
each inhibitor was independent of RhoB. Taken together, the pres-
ence of RhoB reduced cytotoxic activity of TcsL, suggesting that
RhoB acted in a cytoprotective manner.
4. Discussion
RhoB is the only member of the Rho family of low molecular
mass GTP binding proteins that is an immediate early gene product
[11]. The cellular level of RhoB is low in cultured cell lines, due to
repression of rhoB promoter activity by (H/K/N)Ras in a PI3K-
dependent manner [8,9]. The observations of the present study
on TcsL-induced RhoB expression are fully consistent with the
concept that RhoB expression is based on de-repression of Ras/
PI3K-dependent RhoB repression: (i) TcsL treatment resulted in
de-repression of the rhoB promoter and subsequent RhoB expres-
sion most likely based on (H/K/N)Ras glucosylation, (ii) inhibition
of PI3K by LY294002 were sufﬁcient to induce moderate RhoB
expression, (iii) TUDCA-mediated preservation of PI3K activity
(downstream of glucosylated Ras) restored RhoB repression in
TcsL-treated ﬁbroblasts, (iv) TcdBF, that shares all substrates of
TcsL except for (H/K/N)Ras, did not induce RhoB expression, (v)
knock-down of K-Ras was sufﬁcient for RhoB expression in Hela
cells suggests that it is speciﬁcally K-Ras that mediates RhoB
repression. In sum, these observations strongly suggest that TcsL-
induced RhoB expression is based on the inhibition of Ras/PI3K
signaling. The results of this study do not fully rule out the possi-
bility that TcsL induces RhoB expression in a Ras-independent
manner. Analysis of RhoB expression in TcsL-treated cells with
Ras knocked-out would provide evidence on the critical role of
Ras glucosylation in TcsL-induced RhoB expression.
K-Ras has been identiﬁed as the major activator of PI3K/Akt sig-
naling [40–43]. It appears plausible that RhoB is repressed by K-
Ras/PI3K/Akt signaling. In a former study, ectopic expression of
each H-Ras, K-Ras, and N-Ras repressed the activity of the rhoBpromoter as well as the expression of RhoB protein with compara-
ble efﬁcacy [8]. H-Ras, K-Ras, and N-Ras have thereby been highly
over-expressed in NIH3T3 ﬁbroblasts [8], experimental conditions
that do not allow the differentiation of Ras isoform-speciﬁc effects.
TcsL-induced activation of p38 MAP kinase has been reported
for several cultured cell lines, including Hela cells [23] and macro-
phage-like J774A.1 cells [21]. TcsL-induced p38 activation most
likely depends on Rac1 glucosylation, as ectopic expression of
dominant-negative Rac1-A17N was sufﬁcient for the activation of
p38 MAP kinase [44]. This view is supported by the observation
that the activation of p38 MAP kinase correlated with Rac1 (not
(H/K/N)Ras) glucosylation in TcsL-treated ﬁbroblasts. Rac1 and
(H/K/N)Ras glucosylation exhibited distinct kinetics, with Rac1
being glucosylated by about two orders of magnitude less efﬁcient
than (H/K/N)Ras. Comparable observations are also reported for
TcsL-treated rat basophilic leukemia cells [17].
p38 MAP kinase contributes to gene expression either by stabi-
lizing mRNA [45,46] or by promoter activation [31,47]. The results
of this study suggest that p38alpha inﬂuences to RhoB expression
rather through activation of the rhoB promoter than through stabi-
lizing rhoB-mRNA. The rhoB promoter harbors a distal CCAAT box
at 72 and an inverted CCAAT box at 23 respective to the tran-
scriptional initiation site [31,48]. RhoB expression resulting from
HDAC inhibition or induced by UV radiation has been suggested
to result from the binding of activating transcription factor 2
(ATF2) via NF-Y to the inverted CCAAT box (23) in a p38-indepen-
dent manner [49,50]. More recently, the association of c-Jun and
p300 proteins with the distal CCAAT box (72) has been shown
to contribute to UV-induced RhoB expression, with the recruitment
of c-Jun and p300 proteins depending on p38 MAP kinase [31]. The
latter model might be applicable to TcsL-induced RhoB expression
as well. A possible involvement of c-Jun and p300 proteins in TcsL-
induced activation of the rhoB promoter remains to be established.
In TcdBF-treated cells, Rac1 glucosylation results in p38 activation
as well (data not shown). Neither activation of the rhoB promoter
(data not shown) nor RhoB expression were observed in TcdBF-
treated cells, showing that p38 activation per se was not sufﬁcient
for RhoB expression. This leads to the conclusion that RhoB expres-
sion includes both de-repression of the rhoB promoter by Ras inhi-
bition as well as activation of the rhoB promoter by p38alpha.
TcdBF treatment caused RhoB activation (i.e. GTP binding),
although it did not induce RhoB expression. RhoB expression and
RhoB activation thus appeared to be distinguishable effects. In
TcdBF-treated cells basal RhoB was activated. RhoA and RhoB are
identical on amino acid level within the switch regions involved
in GEF interaction [51]. Therefore, it is feasible that RhoA and RhoB
share their activating GEF proteins. TcdBF treatment has formerly
been demonstrated to result in RhoA activation [52]. Those GEF
proteins involved in RhoA activation might mediate RhoB activa-
tion in TcdBF-treated and TcsL-treated cells as well. In TcsL-treated
cells, the level of RhoB-GTP increases (compared to that in TcdBF-
treated cells) due to newly expressed RhoB protein.
The half-life of RhoB protein was less than 1 h in TcsL-treated
cells, which, to our best knowledge, is the lowest value ever re-
ported. Former reports have referred to an half-life of RhoB protein
of approximately 2 h [36,53]. In general, the cellular level of Rho
proteins is regulated by a balance of protein de novo synthesis
and proteasomal degradation [34,54]. TcsL treatment results in
caspase activation [21,20,35,22]. Therefore, the cellular level of
RhoB protein is – besides proteasomal degradation – further regu-
lated by caspase-dependent degradation. This observation was
unexpected, as Rho family proteins have not been described as cas-
pase substrates before. Caspase-dependent degradation appears to
be a speciﬁc feature of RhoB, as degradation of other Rho subtype
proteins such as RhoA, Rac1, or Cdc42 was not observed within the
analysed time frame of 4 h (data not shown). In silico analysis of
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PeptideCutter tool reveals that RhoA and RhoB exhibit a single cas-
pase cleavage site at aspartate-45 [55]. The PeptideCutter does not
predict such a single caspase cleavage site on Rac1 or Cdc42. Cas-
pase-dependent degradation implies direct interaction of RhoB
with caspases. Such direct interaction of caspase-2 with RhoB has
been reported in lovastatin-treated cells [56]. RhoB thus represents
a feasible substrate of caspases.
Differential analysis of TcsL-induced caspase-3 activation in
RhoB-proﬁcient and RhoB-deﬁcient MEFs revealed that caspase-3
activation is suppressed in the presence of RhoB. In TcsL-treated
cells, RhoB expression may be interpreted as a protective response
in order to counterbalance the cell death promoting effect resulting
from inhibition of Ras-regulated pro-survival signaling. RhoB is de-
graded by caspases, which implies a termination of its cytoprotec-
tive activity. Caspase-dependent RhoB degradation may be
interpreted as part of an ampliﬁcation loop aiming to trigger pro-
apoptotic signaling and apoptosis execution. The precise link be-
tween RhoB and caspase regulation remains to be established.
Yet, it is feasible that it involves the RhoB effector protein Rho-
kinase, as Rho-kinase regulates caspase activity in Jurkat cells
[57]. Alternatively, RhoB-dependent regulation of caspases may
involve the effector protein mDia1 [58]. Finally, altered apoptotic
responses including changed expression and activation of several
caspases have been described in neurons lacking RhoB [59].
Based on their capability of inhibiting oncogenic Ras and caus-
ing re-expression of RhoB in transformed cells, FTIs have been
investigated for their potential use as anti-cancer drugs [5]. Their
anti-cancer efﬁcacy, however, is disappointing [60]. The observa-
tions from TcsL-treated cells might offer an explanation for the
poor anti-cancer efﬁcacy of FTI. RhoB appears to act in a cytopro-
tective (rather than a pro-apoptotic) manner in the context of TcsL-
or FTI-mediated Ras inhibition.
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